The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Per Eystein Lønning

Section of Oncology

Institute of Medicine

University of Bergen

Jonas Lies vei 65



Name/email consistency: high



  • Section of Oncology, Institute of Medicine, University of Bergen, Jonas Lies vei 65, Norway. 2003 - 2012
  • University of Bergen, Haukeland University Hospital, Institute of Medicine, Department of Oncology, Norway. 2008 - 2010
  • Haukeland University Hospital, Department of Oncology, N-5021, Bergen, Norway. 2008
  • Breast Cancer Section, Haukeland University Hospital, Bergen, Norway. 2006


  1. Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. Knappskog, S., Chrisanthar, R., Løkkevik, E., Anker, G., Ostenstad, B., Lundgren, S., Risberg, T., Mjaaland, I., Leirvaag, B., Miletic, H., Lønning, P.E. Breast Cancer Res. (2012) [Pubmed]
  2. The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. Lønning, P.E. Ann. Oncol. (2011) [Pubmed]
  3. Evolution of endocrine adjuvant therapy for early breast cancer. Lønning, P.E. Expert. Opin. Investig. Drugs (2010) [Pubmed]
  4. Evaluation of plasma and tissue estrogen suppression with third-generation aromatase inhibitors: of relevance to clinical understanding? Lønning, P.E., Geisler, J. J. Steroid Biochem. Mol. Biol. (2010) [Pubmed]
  5. Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation? Lønning, P.E. Eur. J. Cancer (2009) [Pubmed]
  6. Additive endocrine therapy for advanced breast cancer - back to the future. Lønning, P.E. Acta. Oncol (2009) [Pubmed]
  7. Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status. Lønning, P.E., Helle, H., Duong, N.K., Ekse, D., Aas, T., Geisler, J. J. Steroid Biochem. Mol. Biol. (2009) [Pubmed]
  8. Tailored targeted therapy for all: a realistic and worthwhile objective?. Lønning, P.E. Breast Cancer Res. (2009) [Pubmed]
  9. Aromatase inhibitors: assessment of biochemical efficacy measured by total body aromatase inhibition and tissue estrogen suppression. Lønning, P.E., Geisler, J. J. Steroid Biochem. Mol. Biol. (2008) [Pubmed]
  10. Indications and limitations of third-generation aromatase inhibitors. Lønning, P.E., Geisler, J. Expert. Opin. Investig. Drugs (2008) [Pubmed]
  11. Strength and weakness of phase I to IV trials, with an emphasis on translational aspects. Lønning, P.E. Breast Cancer Res. (2008) [Pubmed]
  12. Adjuvant endocrine treatment of early breast cancer. Lønning, P.E. Hematol. Oncol. Clin. North Am. (2007) [Pubmed]
  13. Breast cancer prognostication and prediction in the postgenomic era. Lønning, P.E., Knappskog, S., Staalesen, V., Chrisanthar, R., Lillehaug, J.R. Ann. Oncol. (2007) [Pubmed]
  14. Aromatase inhibitors--socioeconomical issues. Lønning, P.E., Geisler, J. J. Steroid Biochem. Mol. Biol. (2007) [Pubmed]
  15. Breast cancer prognostication and prediction: are we making progress?. Lønning, P.E. Ann. Oncol. (2007) [Pubmed]
  16. Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer. Lønning, P.E. Ann. Oncol. (2006) [Pubmed]
  17. Does adjuvant therapy with letrozole improve survival in postmenopausal women with early-stage breast cancer?. Lønning, P.E., Geisler, J. Nature Clinical Practice. Oncology (2006) [Pubmed]
  18. Bone safety of aromatase inhibitors versus tamoxifen. Lønning, P.E. Int. J. Gynecol. Cancer (2006) [Pubmed]
  19. Exemestane for breast cancer prevention: a feasible strategy?. Lønning, P.E. Clin. Cancer Res. (2005) [Pubmed]
  20. Aromatase inhibitors--socio-economical issues. Lønning, P.E., Geisler, J. J. Steroid Biochem. Mol. Biol. (2005) [Pubmed]
  21. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. Lønning, P.E., Geisler, J., Krag, L.E., Erikstein, B., Bremnes, Y., Hagen, A.I., Schlichting, E., Lien, E.A., Ofjord, E.S., Paolini, J., Polli, A., Massimini, G. J. Clin. Oncol. (2005) [Pubmed]
  22. Oestrogen suppression--lessons from clinical studies. Lønning, P.E. Best Pract. Res. Clin. Endocrinol. Metab. (2004) [Pubmed]
  23. Genes causing inherited cancer as beacons to identify the mechanisms of chemoresistance. Lønning, P.E. Trends. Mol. Med (2004) [Pubmed]
  24. Aromatase inhibitors in breast cancer. Lønning, P.E. Endocr. Relat. Cancer (2004) [Pubmed]
  25. Clinical pharmacokinetics of aromatase inhibitors and inactivators. Lønning, P. Clin. Pharmacokinet (2003) [Pubmed]
  26. Comparison between aromatase inhibitors and sequential use. Lønning, P.E. J. Steroid Biochem. Mol. Biol. (2003) [Pubmed]
WikiGenes - Universities